European Heart Journal

(ISSN: 0195-668X, 1522-9645)

Subscribe Submit

Table of Contents

2021 - 42 (6)

  • New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease. 
  • Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. 
  • Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. 
  • The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.